MD

Plane-Try-6522

It isn't just the biotech sector. For the past 10, almost 20 years, most corporation have trend towards downsizing or completely eliminated their R&D department in a bid to focus on the operational and business verticals. Most corporation aren't willing to underwrite R&D risk anymore. This has led to the rise and flourishing of startups that, if successful, are acquired, to be integrated into the core business of the buying company. I had a good part of my feet on the venture capital side and quant side of my professional career. **Iova is worth looking into.** They have two lines of product: Amtagvi (FDA approved for advanced melenoma with best in - class ORR, with consistency shown years after FDA approved) and Proleukin. >**52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate** >SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced data demonstrating a best-in-class profile for commercial Amtagvi^(®) (lifileucel) with unprecedented response rates in a real-world clinical, retrospective study in patients with advanced (unresectable or metastatic) melanoma. Amtagvi is the first one-time T cell therapy for a solid tumor cancer as well as the only FDA-approved treatment for advanced melanoma patients previously treated with anti-PD-1 and targeted therapy, where applicable. >The real-world results were highlighted in an [oral presentation](https://www.iovance.com/scientific-publications-presentations/) at the 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT^(®)) and the Center for International Blood and Marrow Transplant Research (CIBMTR^(®)) in Salt Lake City, UT. >Forty-one evaluable patients with previously treated advanced melanoma received commercial Amtagvi according to the U.S. prescribing information at four authorized treatment centers. The physician-assessed confirmed objective response rate (ORR) was 44% (18/41) and the disease control rate was 73% (30/41). Response rates were higher with earlier Amtagvi treatment. The ORR was 52% (12/23) following two or fewer lines of therapy compared to an ORR of 33% (6/18) after three or more lines of therapy. The unprecedented real-world response rates also improved upon the 31% ORR in the C-144-01 clinical trial that supported the U.S. FDA accelerated approval of Amtagvi. >Lilit Karapetyan, MD, MS of H. Lee Moffitt Cancer Center & Research Institute stated, “The real-world response rate builds on existing clinical data and supports consideration of lifileucel as soon as possible after immune checkpoint inhibitor treatment. An overall response rate of 44% was observed in the full cohort, with a 52% response rate among patients treated in earlier lines of therapy. I am encouraged by the potential for an increasing number of patients to benefit as adoption of TIL therapy continues.” >Daniel Kirby, Chief Commercial Officer of Iovance, stated, “The real world Amtagvi data with impressive response rates, paired with unprecedented five-year durability and survival data, demonstrate a best-in-class profile and better outcomes in patients treated earlier.” >Previously treated advanced melanoma represents an unmet medical need with more than 8,000 annual U.S. deaths.^(1) More than half of patients treated with first line standard of care will progress within 12 months.^(2) The U.S. FDA granted accelerated approval for Amtagvi in February 2024 based on ORR and duration of response (DOR) from the C-144-01 clinical trial. The published [final five-year analysis](https://ascopubs.org/doi/10.1200/JCO-25-00765) demonstrated unprecedented durability and follow-up in previously treated advanced melanoma patients, with \~31% ORR, median DOR of 36+ months, and a 20% five-year overall survival.^(3) Iovance is conducting TILVANCE-301, a Phase 3 clinical trial in frontline advanced melanoma, to confirm clinical benefit. >1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2025 Estimates. [https://seer.cancer.gov](https://seer.cancer.gov/) (accessed February 2026) 2. Larkin J, et al. NEJM; Robert C, et al. Lancet; Tawbi HA, et al. NEJM 3. Medina T, et al. JCO Source: [https://ir.iovance.com/news-releases/news-release-details/best-class-real-world-data-support-early-amtagvir-treatment](https://ir.iovance.com/news-releases/news-release-details/best-class-real-world-data-support-early-amtagvir-treatment) **Using what made Amtagvi/ lifileucel successful, Iova has made positive in-road into cell therapy for soft tissue sarcomas with a high 50% ORR.** >Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas *50% Objective Response Rate (ORR) in Advanced Sarcomas* >*Significant Market Opportunity with More than 8,000 Patients Diagnosed* *Annually in the U.S. and Europe* >SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced positive early data from a [pilot clinical trial](https://clinicaltrials.gov/study/NCT05607095?cond=sarcoma&intr=TIL&rank=6) led by Memorial Sloan Kettering Cancer Center (MSKCC) and supported by Iovance of lifileucel in patients with advanced (metastatic or unresectable) undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who were refractory to at least one prior line of systemic therapy. >Among the first six evaluable patients treated with lifileucel monotherapy, physician-assessed confirmed ORR by RECIST v1.1 was 50%. All evaluable patients had advanced disease, were refractory to prior therapy, and had significant disease burden, with a mean sum of diameters of 117 millimeters at baseline and a mean of more than two prior lines of therapy. Patients experienced deep responses that improved over time, consistent with lifileucel in melanoma, non-small-cell lung cancer, and other solid tumors. The safety profile was favorable and consistent with lifileucel therapy in other indications. Based on these results, Iovance plans to commence a single arm registrational trial in second-line advanced UPS and DDLPS in the second quarter of 2026 and will engage with the U.S. Food and Drug Administration (FDA) on an accelerated path to expedite approval. Iovance also plans to explore lifileucel in other high grade soft tissue sarcoma subtypes with high unmet need as part of its clinical development program. >UPS and DDLPS are high grade, aggressive soft tissue sarcomas associated with poor prognosis that impact more than 3,000 patients in the U.S. and more than 5,000 patients in Europe annually, including more than 3,500 patients with advanced disease.^(1-3) There is a high unmet medical need for new treatment options for second-line patients with recent clinical studies reporting ORRs of less than 5%, median progression-free survival (mPFS) of \~2-3 months, and median overall survival (mOS) of \~9-10 months.^(4-6) >Lauren Baker Banks, MD, PhD, Sarcoma Medical Oncologist, MSKCC, stated, “In the first clinical trial of a TIL cell therapy in UPS and DDLPS, one-time treatment with lifileucel demonstrated compelling and unprecedented response rates with the potential to address a significant unmet need in patients who are refractory to frontline standard of care. Patients with UPS and DDLPS suffer from high disease burden, poor quality of life, and a lack of effective treatments, including no approved immunotherapy options. In the second-line setting, mPFS for many patients is only a few months with mOS less than a year. We look forward to presenting these results at a medical conference in 2026.” >Dr. Brian Gastman, EVP Translational Medicine and Research at Iovance, stated, “The exciting clinical results show that lifileucel could offer a new, highly efficacious, and durable immunotherapy option in two aggressive forms of advanced sarcoma and further illustrate the promise of our TIL cell therapy platform to offer meaningful clinical benefit in multiple solid tumor cancers. Chemotherapy with extremely poor efficacy remains the second-line standard of care for these patients after progression on front-line chemotherapy. We look forward to bringing lifileucel to UPS and DDPLS patients as quickly as possible.” Source: [https://ir.iovance.com/news-releases/news-release-details/iovance-announces-positive-results-first-clinical-trial-til-cell](https://ir.iovance.com/news-releases/news-release-details/iovance-announces-positive-results-first-clinical-trial-til-cell) More: [https://ir.iovance.com/news-events/press-releases](https://ir.iovance.com/news-events/press-releases)

Bilbo_Butthole

Good god I’m up so much on ghey-MD

Creative-Doctor3118

Plot twist, it was MD Burry.

HeftyBox3580

Thermo puts was easiest play this year. They laid off my local DC/MD sales account rep of 10+ years and now my account rep is 10 states away in Houston

DesignerSea494

Nothing like the greasy stripper pole route to MD.

BaxBaxPop

It's a scam. Almost all healthcare business startups are either MD-owned or VC owned. In neither of those cases would they be reaching out to just some guy for $50k. Also, $50k for a 10% ownership of just about any medical clinic is an absurd payoff. Many clinics make $1m per year. Too good to be true.

Revelati123

"Though war pestilence and famine ravage the land, stonks only go up! PRAISE ALLAH" \-Dr. Jesus H. Trump MD.

goktan507

Thanks, I appreciate it alot. I will get started soon. I already spent a few days on learning the terminology, the purpose of option trading etc but as you said, there is alot to learn and it gets overwhelming when things don't click and you keep reading/finding same things over and over again. I use AI to summarize so that I can memorize/re-visit easily, and sometimes to explain it in different ways that I can understand. After some time, the agents learn about your style, especially if you are using local agents + MD files for skills and memory. Hoping to share some good hits here in the future, thanks to you all :)

EmbarrassedPart1256

Dang good thing I just opened a Fidelity account back up & can trade OTC! You make a good argument; I always liked their products, living in MD 🤙

callsonreddit

He is an MD too

phatelectribe

RXDX - Prometheus Biosciences. A friend is a researcher who worked for them. Probably the most brilliant man I’ve ever met. Genius level MD. The stock was at $27 when I realised he worked for them and I said to myself I should buy but I procrastinated and bought in around about a year later at $170. Beyer swooped in and bought them for $200 per share. Not a bad return but 7.4x would have been a lot nicer.

LlcooljaredTNJ

Jesus Christ, MD

orsomeshitidk

I think there’s intelligence classes like there are economic ones and if you’re in the middle class of intelligence you can realistically do 90% of white collar work so unless it requires a license like being a fuckin MD or something, lie if you have to to get the job. Fuck em.

sauronII

Let the bears have some hope. Jesus MD is going to get a big bear hug from Winnie the Pooh, if that‘s not ATH news nothing is. Praise be to Allah!

MrRobotFancy

i think you're confusing a dream of yours with an episode of *Dr. Christ MD*

Nudge55

US does not depend on MD oil

MilesDelta

Problem with LLMS is they are stupid don;t use GPT it sucks, use claude or an open source model, Open claw has a bynch of security flaws btw. So be super careful, prompt injection risk is real. I don't think they will lead to AGI, it is likely some other tech that will. Pro tip, use MD files to save xontext on Claude and you can do proxy reinfrocemnt learning and have the chat update context so it remembers. Saves a ton on compute credits

sQ5FWKjwbWd4QzSZduqy

A law degree is closer to an MD (not including residency) than a PhD.

Retaining-Wall

Doing the MD in an A sorta way.

banditcleaner2

MD 2020

JelliedHam

Dude, read your employment documents. You've got a degree, so I'm guessing you're at least literate. As long as you're not working for some bro in his basement I bet this company even has a code of ethics and compliance. Finally, why don't you take all the money you likely don't have, put it in your pocket, and go and ask the PM or your MD what the policy is. Depending on what your firm trades you likely have a restricted list, but as long as you're not managing private SMAs for accounts you might be good if you start away from those. Don't complain to us ya dummy, go look it up and ask ffs. Nobody there is going to blame you for asking. Hell, just talk to one of your coworkers first if you're not totally autistic.

Ok-Amphibian3164

Two HC-130J Combat King II aircraft and MD-500 Defender (MH-6 Little Bird) helicopter

orsomeshitidk

A6 Hibino Free Diary and a A5 Midori MD, both grid lined. Highly recommend both.

MuestrameTuBelloCulo

FWIW the new regs on controlled substances, including Adderall, are nonsensical. My MD is limited in the amount she can subscribe, so she's dropping dosages for her patients. Had a dosage that finally worked, and then this insanity. Thanks, Obama!

coolest35

Actual double board certified MD. No snake oil salesman here.

LabCoatLunatic

But none of what he says sounds like true severe and rapidly progressing dementia. I hate the whole "his health is in rapid declined" argument. The fact is that for his age, his stamina is remarkable. He plays golf, flies to meetings and gives energetic speeches when needed. The same can be said for what Biden did at his age. Ask yourself...how many almost 80 year olds do you see out just doing shit, let alone golfing and traveling the world attending meetings and briefings. Even if he's hopped on coke, Adderall, or falling asleep half the time. I'm an MD who deals primarily with the elderly and if I had a patient he and Biden's age just "doing shit", I'd be very pleased with their activity level. He just genuinely sounds like a babbling idiot. He doesn't have to be demented AND a painfully narcissistic moron to be doing what he's doing. I say this as someone who has zero respect for him and nothing but I'll will towards he and his entire vile family. I happily voted against him 3 times.

eagle0504

There is no single switch you can flip in SEC filings to bulk export “retention metrics” because the SEC does not mandate a standard DAU or NRR metric, and companies disclose them in different sections, formats, and even with changing definitions over time. In practice, you either have to combine a bit of manual work with a “brain friendly” workflow, or lean on tools that already structure this kind of KPI data. A practical approach is to identify a small KPI set you care about, then consistently pull those from each company’s 10 K and 10 Q MD&A or KPI sections into your own sheet or database, accepting that Snap’s DAU or HubSpot’s NRR will not be defined exactly like Netflix or Spotify. If you want something more automated, your best bet is to use a financial data API or LLM based extractor pointed at the filings or earnings decks, then spot check the outputs against the original documents so you are not blindly trusting the model

TTP222

I invest in bios, and I understand some people don’t like them, but here are two I feel strongly about: $SLS - It’s only available at these prices because of past toxic financing deals which are behind them now. Some of the best cancer hospitals in the world are part of their development in Memorial Sloan Kettering, Moffitt Cancer Center, and MD Anderson. Their current phase 3 REGAL trial is derisked as they come. Here is the best DD I’ve ever seen on it: https://www.reddit.com/r/ValueInvesting/s/s3pjFlirzN $CING - new time released, once daily ADHD med about to hit the market. Experienced management and ownership team, global patents, and a small float that should lead to huge returns. Upcoming NOA and PDFUA catalysts within the next 30-90 days.

Common-Tradition-231

I have tax lien invested in Baltimore, MD. I actually won 3 liens in my first auction. This was years ago. I learned by doing research and reaching out to people who were doing it. Ned the owner of crabpropertiesllc. was willing to give me some advice and even connected me to the lawyer he used. Way more valuable than any course. If you want to learn biggerpockets is a great place. Also local realestate investment associations (RIA). In Baltimore, if the property is deemed vacant, you can start foreclosure immediately. All the properties were redeemed. One property was redeemed after I started foreclosure. In Baltimore, there is a pretty good system where you register your attorney if you start the foreclosure process. By doing so, the city ensures your attorney fees are calculated and paid upon redemption, along with interest. Most people bid and hope for redemption. I transitioned into rehabbing properties that were a better fit for me, but I am now looking to invest in tax liens again because I live abroad, and remote flipping is impossible. People say tax lien investing is sleezy. It isn't, the city provides a service, trash pick up, policing, schools, parks, etc., that residents agree to pay for by living in the city. When people don't pay taxes, the city's only way to enforce is to auction off the property. The investor loans the municipality money. And for the loan, the investor is given a small interest payment. Alternatively, if the city cannot raise money via taxes, it will have to sell bonds, thus raising everyone's taxes to pay back. If people aren't paying taxes, selling bonds to make up for short falls a vicious feedback loop. Lastly, many properties that don't redeem are usually vacant, public nuisances that cause blight to an area. Tax lien investors generally sell to property rehabbers, who take a property that would not qualify for financing and get it up to standards that a family can finance.

1bizzyone

TACO approaching Dunkirk, MD, probably another 30 min in the air says TheAirTraffic

shortitforever

Bull spotted at local circle k buying MD 20/20 and kratom pills

BreakfastMedical5164

thats cuz daddy upstairs (MD) cant actually write what they think, there is zero chance oil goes to 70 by eoy

Zipski577

Lots of MD promising therapies in clinical trials right now that will be game changers for the disease… don’t worry you’ll still be able to work if you hold through this upcoming crash

ExigentCalm

Once you’re diagnosed with a serious illness you are uninsurable. Nobody will sell any kind of life insurance to someone with MD.

Creative_Squash_1083

Counter-analysis: 1. **THE CASH IS IN THE BANK (AND YOUR SHARES ARE DILUTED).** The $10.5M was raised via a PIPE involving Series A preferred stock and blocks of Series B and C warrants. Raising $10.5M on a sub-$5M market cap severely dilutes the retail float. The touted "extra $20M" arrives only if warrants are exercised, creating a permanent ceiling of selling pressure (warrant overhang) that caps upward momentum. 2. **CEO IS PUTTING HIS MONEY WHERE THE INSTITUTIONS TOLD HIM TO.** In micro-cap rescue financings, a CEO buy-in is rarely a voluntary show of confidence. It is a structural requirement demanded by institutional investors. If insiders refuse to put capital at risk, the institutions walk and the deal dies. 3. **MD ANDERSON "PARTNERSHIP" IS A VENDOR CONTRACT.** This is semantic spin. MD Anderson was added in February 2026 as a clinical trial site, not a commercial partner. Biotech companies pay hospitals to run trials. It is a paid vendor relationship, not a medical endorsement. 4. **THE JUNE CATALYST IS A PHASE 1 TRAP.** The mid-2026 data for ATR-04 and ATR-12 comes from early-stage trials designed to prove safety and dosing, not efficacy. Even with positive data, Azitra is years and tens of millions of dollars away from FDA approval. This guarantees future massive dilution to fund Phase 3. 5. **THE COSMETIC SLEEPER IS A DESPERATE PIVOT.** Launching a cosmetic program immediately after a distressed financing is a standard micro-cap distraction. It generates retail hype and promises near-term revenue while cash-burning clinical trials face long regulatory timelines in the background. **The Play:** The volume is surging because warrants are being prepped to dump. The bottom is not in at $0.24. We are consolidating for the next leg down. Analysts have targets at **$2.00+** to create exit liquidity for the institutions, and retail is walking right into the trap.

69downunder

let me bring another one brtx : start with the ugly: just put out 10-k, real ugly as expected, just some from: At current burn rate, it has approximately 3.3 MONTHS of operating cash remaining without new capital. Even reducing burn by 30%, runway extends to only \~5 months. The company MUST raise capital before June/July 2026 to maintain operations. 10-K MD&A specifically notes 'possible second period + reverse split' as compliance paths. Management is explicitly signalling that a reverse split is being considered as a compliance mechanism. Historical context: BRTX has executed 4 prior reverse splits. The question is not WHETHER a reverse split occurs — it is WHEN and at what ratio. moreover, $3.326M in stock-based compensation was recognized in FY2025. For a company with $359,700 in total revenue, stock-based comp represents 925% of annual revenue. This is structurally standard for clinical-stage biotechs, but means management is compensating itself substantially with equity at prices that are continuously declining. At $0.29/share, the options and restricted stock granted to management have questionable retention value — many prior grants are likely deeply underwater. and there are some more, you gotta look up...! but tomorrow, at ORS Conference, Francisco Silva will present \~45-patient blinded interim (largest dataset yet) - Phase 2 Blinded Data. you gotta dep dive into management team (and more). reason i brought this up is because the man, Silva, is a genuine stem cell pioneer — Section Editor of the Journal of Translational Medicine, original discoverer of the BADSC 3D aggregate, co-inventor of the hypoxic culturing protocol that gives BRTX-100 its disc-environment survival advantage. check it out. check also ceo Lance Alstodt and the others. obvioulsy there are some possible scenarios for ORS data, bear/neutral/base/bull. check it out and take care! https://firstwordpharma.com/story/7142778#:\~:text=Francisco%20Silva%2C%20BioRestorative's%20Vice%20President,Chief%20Executive%20Officer%2C%20and%20Chairman.

GlobalManHug

Except the analogy would be if MD kept dangling a few fries for you as you got up.

outoftownMD

MD here. Wut?

AllPeopleAreStupid

I wouldn't put much stake in any of the crap you said. I work in the industry. Everyone is required to have testing, everyone is required to put the lab work on the label ot some extent. in my state they have QR codes so you can actually read the entire lab work. "Safe, clean cannabis." is as worthless a statement as "Cage free chicken," "cage free eggs," "humanely farmed," or even "Kraft Real Cheese." There is a lot of "Certified" this and that that does not mean anything besides that they paid a fee to some organization that then let them use such logo. Here's a worthless Cannabis statement for you, "Safe, clean Cannabis, organically grown in the USA, 3rd party tested, voted favorite strain of "yadda yadda," packaged in environmentally friendly packaging." I could go on but I think you get it. Then again they put dumb shit like this on products because people think they mean something, when in fact they don't. Like "Kraft Real Cheese" is in fact not "real" cheese, its "Real Cheese." Anyways we all have to follow pretty strict regulations in most states. You will know if a company isn't good because they will have regulatory violations or recalls. There was a company in MD called Forward Grow that was forced by the state to sell their license for using unapproved pesticides. So things do happen and people do get punished sometimes.

TomorrowSavings7579

In Accident, MD we've switched over to home made gas

FU888

Again because: Absence of SEC filings not the main issue. If you read the whole report then you can see the narrative vs reality. "**The narrative pushed to retail investors** (via HydroGraph's website, investor deck, GlobeNewswire PRs, LinkedIn/X updates, conferences, and retail forums) is classic "graphene moonshot" hype: * **"Leading commercial manufacturer"** of the purest (99.8%) graphene using revolutionary, eco-friendly detonation tech (Hyperion system) "unlocking the promise of graphene for the world," "highest quality at greatest cost efficiency," "industry first" for consistent batches at scale. * **Regulatory wins = immediate market unlock**: US EPA TSCA approval + UK/EU REACH clearances (announced Feb 24, 2026) mean "commercial scale graphene sales" are now possible across North America/Europe; "three key milestones that meaningfully expand our commercial markets." * **Scaling explosion**: New Austin, TX headquarters + second production facility (LOI with major industrial gas supplier); building more reactors; "centralized production" targeting "hundreds of tons" capacity; low-capex model could deliver "$100M+ sales" from $10-15M investment. Texas = "central hub" for US ops. * **Customer/revenue ramp**: 60+ active customer programs (auto, defense, composites, lubricants, concrete, etc.); "larger purchase orders and long-term supply agreements" imminent; "first contracts expected"; partnerships (GEIC Tier 1, Hubron, etc.) will drive explosive growth in 2026. * **Financing validation**: Recent C$30M LIFE offering closed March 5, 2026 (at C$5.10/unit) proves strong demand and funds the "Texas scale-up." Market cap run-up reflects "year of transition" to profitability. Retail sentiment (forums, X) often amplifies this into "DoD/defense plays," "revenue explosion 2026," and "superior to competitors." **The reality from official filings** (latest SEDAR+ MD&A for FY ended Sept 30, 2025 dated Jan 27, 2026 + Q1 ended Dec 31, 2025 filed March 2026; financial statements; OTC uploads): * **Revenue**: Still negligible. FY2025 total sales = **$43,051** (up from $6k prior year). Q1 FY2026 = **$19,685** (mostly small research quantities/services). Inventory produced to date: \~500 kg. No major/long-term contracts or meaningful product revenue. * **Losses & cash burn**: FY2025 net loss = **$8.15M** (worse than prior $5.3M). Q1 loss = **$3.15M**. Operating cash outflow: \~$4.8M (FY) / $2.5M (Q1). Accumulated deficit now **$26.5M**. Never generated profit or positive cash flow from operations. * **Production status**: One operational Hyperion reactor (10 tonnes/year theoretical capacity) in Kansas since 2023. Two additional reactors under construction (Jan 2026) for validation before possible Texas move. Texas "production facility" = early LOI + Austin HQ lease/leasehold improvements only **no commercial output yet**. All inventory costs are expensed (no capitalization). * **Dilution**: Shares outstanding exploded to **\~340–347 million** (weighted average 333M in Q1). FY2025 + subsequent: multiple private placements, warrant/option exercises, and the recent C$30M raise (adding \~5.88M new shares + warrants). Heavy ongoing dilution to fund burn. * **Liquidity & risks**: Explicit "material uncertainty related to going concern" in every MD&A. Survival depends on continued equity raises; "no assurance" of funding or commercial success. Risks include scaling execution, market adoption, competition, regulatory conditions, and need for more capital. * **Outlook language**: "Expect" larger orders "within calendar 2025" (didn't materialize at scale); "targeting" Texas expansion; clearances "enable" pursuit of agreements but cautious, no quantified revenue guidance or timelines for profitability. **Bottom line, the gap**: The retail story sells **"we are a commercial graphene producer scaling now with regulatory green lights and big contracts coming"** (positioning it as ready for multi-billion markets). The filings paint tiny sales, accelerating losses, heavy dilution, and all future growth still "expected" and fully dependent on perfect execution + more raises.

El-Hombre-Azul

Start your carreer working in goldman sachs at age 21-22 and be born into a well connected family, your father is friends with the CEO of the margin call hedge fund that will make you MD by age 32

Ragepower529

I highly doubt they set up there AI correctly for me right now Claude is doing fine managing 14 db bases in my app. It has a total of 11 agents and fees into one another to keep pushing updates while also updating its own MD files and using git to see changes. All changes start with a new context window that allows further changes and development. I think i use around 1600-2000 context right away but runs smooth enough.

sunnythehamster

For clarification I'm an MD who works for a biopharma in clinical development and I don't regard the data as promising. I would suggest that I'm a better person than the one who is trying to convince gullible redditors to gamble their life savings on a lottery ticket biotech

MilanMelange

MD Radiologist here. I can just say that all radiologists journals are full with articles about ai usage. For the last 5 years. I did not dig into this company but imo there is no moat. There are many others doing this, most are private. And by the way 10800 brain scans is nothing, it is 1 small Hospital with a Neurologe emergency / stroke department. Maybe they execute better than all others idk

TheHiveMindSpeaketh

You should read at least the most recent 10-K, but 'reading a 10-K' doesn't mean reading every word. There's a lot of boilerplate (most of the risk factors and notes are usually skippable if not doing a deep dive). I'd focus on the business overview, MD&A, and financial statements.

InvincibleRoman

your an MD, you'll get a return on your investment in 40 years. They punish us investors so that the medical class can slave away all their life and think its normal.

Public_Sandwich6941

Honestly, I don’t read full 10-Ks unless it’s a large position. I usually look at summary financials, earnings presentations, and maybe the MD&A section. Full reports are dense and time-consuming, so I focus on the key metrics that matter for that sector.

basementdweller263

I don’t read every line unless I’m seriously considering a position. Usually I skim the 10-K first. Business overview, risk factors, cash flow statement, and then I’ll dig into the notes if something looks off. The MD&A section is actually more useful than people think. Quarterlies I treat more as updates than deep dives. There’s definitely a learning curve, especially across sectors. But after a few reads you start recognizing the patterns and what actually matters vs filler. If I’m just buying broad ETFs though, I don’t bother.

LongevitySpinach

Not a fan of the man, but this idea isn't entirely garbage. I think some version of Universal Basic Equity can be a part of the solution to the growing income inequality and future disruption. Won't replace $100k annual salary, and coming up with $1k to deposit to get the match is a trick if you're unemployed, homeless and hungry. Doesn't help the worst affected. Should be universal like the baby trump accounts. UBI - Universal Basic Income - widespread acceptance that this will probably be necessary UBE - Universal Basic Equity - most people never heard of it, but it makes sense that if machines are taking over the entire economy that the people should have at least part ownership in the means of production UBS - Universal Basic Services - This is probably the most important. The LLM's are already providing a near universal service in free chat and analysis. The most obvious place where this can have a massive impact is medical care. With a few peripherals, a $10k superintelligent robot will be able to diagnose and treat illness better than a human MD, lowering the cost of doctors visits close to zero, excepting things requiring advanced testing equipment. They could do dental work, too. They can do nursing work and wash dishes, and do laundry. yada, yada. Mostly just the cost of electricity.

elbay

I’m lacking like 14 points in BMI but I do have an MD does that count?

Correct_Proposal_409

You can use your own rhetorical "many trials have failed and therefore this is destined for failure" for any therapy being developed. Historical failure rates raise the bar, but they don't determine the outcome of a mechanistically unique therapy with a demonstrated CNS pathway correction. Here we have a genetically validated pathway (GBA1), plus strong evidence of Gcase dysfunction and corresponding lysosomal lipid accumulation in a good portion of idiopathic cases. If you are an MD, you should understand the relevance of GBA1 PD and Gaucher's-- they share the same GBA1 mutation. Life-saving, disease-modification was achieved by addressing dysfunctional Gcase, with GluSph being the most important biomarker for confirmation of target-engagement and disease progression. Of course, these Gaucher's therapies do not cross the blood-brain barrier. GT-02287 addresses dysfunctional Gcase in the brain. The reasonable take would be, "let's see how reducing GluSph levels translates to reduction in downstream biomarkers and in clinical symptoms in Parkinson's cases over a longer timeframe." Not, "I'll eat my shoes if this works". Hard to take you seriously when you are so seemingly dismissive without offering mechanistic reasoning to back up your statements. It almost seems as if you want it to fail. Do you work for a competitor of Gain? That would explain it. "Your post history is rabid with support of this stock... you are looking for someone to buy your bags." This is an immature, ad hominem assumption that does not address the science. Yes, I believe strongly in this treatment. I think it is the most promising PD treatment being developed, for the reasons I've detailed in my many posts. I'm lucky to have a very low basis. I *am* looking for BP to buy my shares for multiples above by basis. Not retail investors. I won't convince you-- not trying to convince you. But readers should understand that your baseless dismissal has no bearing on what many experts think is a very promising development in Parkinson's disease treatment. Maybe we should follow-up in September and see how durable the data is with the 16 out of 19 patients who elected to continue with the treatment despite the tests and additional lumbar puncture, many of whom have reported improvements, along with their clinicians. Beyond UPDRS, some of these reports may be anecdotal, but if they truly have regained sense of smell, this does not happen with placebo.

Worried_Quarter469

The inverse Micheal Beary MD, the Michael Bully if you will

sunnythehamster

I am an MD who works in clinical development for a biopharma. I've seen trials with much better clinical validation of the target go belly up.You are reaching heavily. I am not denying that this drug reduces GluSph, but I will eat my shoes if this leads to clinically meaningful changes in prespecified clinical endpoints in a phase 2 or 3 trial. Your post history is absolutely rabid with your support of this stock. You are looking for someone to buy your bags. If this drug goes to a large phase 2, I will probably short it before readout because I know how this ends.

Skibbittbeebop

TMDX just popped on latest earnings — I invite you all to evaluate this company. The product is basically a circulatory system for organs procured for transplant. That may not seem important but what that does is GREATLY increase the time one has to move and transplant an organ, thereby vastly increasing the availability and viability of already scarce organs. They just got an Investigational Device Excemption for hearts, which will add on to their already FDA approved devices for Lung and Liver. And they have best earnings four quarters in a row. They just expanded their office space. Why I think this is a very good long term play is: 1) the diseases served by transplant are from diseases of vice (smoking, drinking, uncontrolled diabetes), which will never truly be conquered non-surgically because treatment requires patient compliance. 2) immunomodulating therapies are moving closer and closer to safely creating universal organs. We are years away but the point is this is revolutionary science and I believe transplanting organs for longevity is going to be a very real thing in 20 years. Fair warning: I’m a retard MD and we notoriously make bad investment decisions. This one has been paying off well. This isn’t financial advice, just something that’s actually in use that is showing up in more and more hospitals.

maryjanevermont

iBRX straight growth ahead with growing approvals pulse now having trial at MD Anderson,European trials100% VOO should have pullback soon.

LarryStink

Michael Burry, MD

Run4theRoses2

12,500 AML CR2 / CR3 Patients who'll be Eligible each year + 40,000 AML CR1 patients, each new year -to add to the 100,000 patients currently in remission who will immediately be eligible and benefit from Gps Immunotherapy. and if you think the FDA isn't going to approve Gps Condiditonally for CR1, after seeing 4x Increase in survival to 24-30 months for Cr2 with NO SIDE EFFECTs, near 100% Quality of Life, combined with the MSKCC Phase 2 CR1 TRIAL DATA of 67.6 month MOS - Better than Transplant, if you think the FDA is going to wait 5 years for a trial, when the Chair of MD ANDERSON's Leukemia Dept., running the Global P3 requested Expanded Access to GPS for CR1 patients, and they also submit that EAP DATA. you have more research to do u/Away-Information9841

maryjanevermont

iBRX. PLSE you are welcome the story- IBRX will treat Lymphopenia Comman problem on cancer therapies. approved now in UAE, EU next for bladder cancers. outstanding results in small groups with glioblastoma pLSE new treatment for atrial fib. 100% success, 96% at one tear. Procedure 1x 6-8 min. just started clinical trial at MD Anderson. very early stories. IBRX will make millionaires but more important save lives . Already has a safety profile and case reports

mikey_rambo

Lmao yeah he turned into MD orange coat quickly

ArthurDent4200

MD isn't so bad and you should be able to deduct half your SPAXX growth from your state income. The killers are CA, NY and CT where if you don't meet a threshold you deduct nothing.

wowmomcooldad

Spanberger is now (just got into office) going to require data center owners/operators to front “all” their energy costs. At least that’s the plan, but she’s one of a few leader coming out saying that. Not even MD’s gov has the nerve to do that…

wsb_crazytrader

An MD that makes money? Craziest year yet.

Ass-Pounder-4000

Dr. Mantis Toboggan MD

wasabiburning

The recent GradPlus loan changes have capped total loans at $200k for professional programs (like MD). This means fewer people can become doctors. The recent GradPlus loan changes have capped total loans at $100k for non-professional programs (like CRNA, NP, and PA). This menas fewer people can become the people that reduce doctor workload. Our future: * Fewer doctors * Fewer advanced healthcare pros who reduce doctor workload If the loan limits aren't fixed ASAP, this is going to have devastating effects on healthcare.

AverageNo130

A federal bill designed to block marijuana businesses from claiming standard tax deductions even if marijuana is rescheduled has gained its 15th sponsor in the House and Senate, and its second new sponsor this week. House (HB 1447) * Jodey Arrington (R-TX) * Vern Buchanan (R-FL) * Blake Moore (R-UT) * Gregory Murphy (R-NC) * Adrian Smith (R-NE) * Nathaniel Moran (R-TX) * Charles Edwards (R-NC) * Gary Palmer (R-AL) * Pete Sessions (R-TX) * Andy Harris (R-MD) * Andrew Clyde (R-GA) * Michael Lawler (R-NY) Senate (S. 471) * James Lankford (R-OK) * Pete Ricketts (R-NE) * Ted Budd (R-NC) * per MM

haze_from_deadlock

These days, the boards are filled with these healthcare jobs requiring a MD or DO along with board certification that pay only $190k

ETFBro4DaWinz

Hello. James Mason, MD at Philedelphia Logistics, but you may know me as u/BumsRFunny5797, moderator on r/butt_plugs

ai-moderator

#TLDR --- Ticker: HIMS Direction: Up Prognosis: Long Shares & LEAPS for March 2026 Credentials: "Regarded MD" Secret Weapon: Liposomal delivery (bypasses Big Pharma patents) Strategy: OP argues Hims is playing 4D chess. The recent product "pull" was a publicity stunt. Hims is partnering with Strive Pharmacy to use liposomal technology, which bypasses Novo Nordisk's delivery patents. With a major GLP-1 patent expiring in March 2026, Hims is positioning to legally flood the market with generics while using the current price crash to execute cheap buybacks.

SpringLong7259

You forgot these gems -Supreme sales license (any day now) -Hadley Ford at Ianthus -MARI/WAYL and Ben Ward Fleeing the country -Gene Simmons (Invictus MD) -THC Biomed and the [Ferrari](https://old.reddit.com/r/weedstocks/comments/60dvbw/outside_of_thc_biomed_i_see_this_ferrari_often_is/) Its fun to go look at press releases, scams and all the things happening 8 years ago.

EnvironmentalCan381

👆not true! I am also a pharmacist. Please actually read the law congress passed regarding compounding medication. MD can prescribe compounded medication if necessary and it has explicitly stated it’s up to the prescriber. That is why we do semaglutide with vitamin b12 because b12 has shown some patients have no side effects to drug. Plus we can give different less dose to titrate. You think Iam bullshit? then go prove. That is what courts been saying. prescribing md do not have to prove.

blalah

Bottle of MD 2020 and those fingerless wool gloves

SuspiciousTruth1602

What's your yoe? No offense but that is a terribly innocent take I'm 9yoe, I can feel the damage in doing dictating instead of writing, key core areas id know by heart I now generally know what they do, not specifically 1000 lines of Claude MD docs are not adequate to describe 1m loc

NewDawn101

I am a doctor, Mantis Tobagin MD

the_Q_spice

FDX. Pretty clearly gapping upwards the last few days and had an utterly massive target upgrade from $295 to $380. Pretty glad I hopped on at $300 because there's a ton of positive catalysts going for it right now (likely MD-11 return in March-May, Freight spinoff adding $20B in value just to existing shareholders alone, and record profitability and increasing efficiencies of scale).

Virtual-Ducks

First you get a PhD in economics/finance/computer science/math, then you would at a finance company with a team made up of some of the world's smartest humans where you conduct thorough, advanced analysis over the course of weeks/months/years. Or perhaps you have some advanced degree (MD, engineering, etc.) which gives you some special insight into the impact of some startup that others haven't seen yet.  Otherwise, buy VT. You are not going to be able to compete with finance groups spending literally millions of dollars on large teams of world experts trying to answer this question. 

MetatronicGin

My buddy's gay stripper name was Rich Sparkle, Dr. Wewe MD

the_Q_spice

As someone who actually works at an airport, CRJs aren’t “aging airframes”. MD-80s and -90s? Yeah 737-300, -400, and -500s? Sure. The A300-600s I work on (that ceased manufacturing in 2007, and most of the airframes I work on began their lives in the 1980s)? *Definitely*. But the CRJ line only ceased manufacturing in 2020. They are by all measures, *very* modern aircraft. They began manufacturing them in 1991 with the 100/200, and most models still flying are the more modern 700/900/1000 (and other variants) that only started production in 1999. Hell, practically all 737s, 747s, 757s, 767s, 777s, and even some 787s are older.

Bright-Efficiency614


MayaIsSunshine

You're an MD, pick up an extra shift and you'll have it back 👍

waterpup99

I sold a while ago to reposition to AMD and semiconductors overall. I still think Nvidia has upside but MD is better position to take market share and Nvidia may lose pricing premium in the coming months and years which has driven their crazy profitability

CarcossaYellowKing

I’m conflicted because it is the earnings season that covers the holidays which is the busiest time of the year in the package industry, but I don’t know if that plane crash and their MD-11 fleet being grounded will be enough to cause a serious earnings miss. I might do 2 puts lol.

puppetmstr

Nah, where is the moat on Meth? Despite it now having 50% marketshare, Meph and MD are coming for it like Apple pay and Klarna for Paypal. 

ThreeSupreme

Oh ok. Yeah, U should not leave a trade opens, when leave your computer, when U are day trading. Does the trading platform that U use, give U the ability to set "Trailing Stops"? 

daviddjg0033

Mid caps and small caps have worked well if you bought in the past six months. VXF IWM the Russell MD or mdy etf.

Select-Point-7312

The MD of my trading desk laughed at me when I said I full ported IMSR at 7. Today everyone was spamming +25% in the desk chat. Fat W.

Normal-Intern6932

Great question.   NAKA kindly MD is a bitcoin treasury company that fits this scenario except Bitcoin instead of land.  I own some

TheNplus1

Calls on E-MD

Enough_Summer7073

I'm in academia, so I am in the loop of what breakthroughs people are actively researching, not so much on which companies take up the research and commercialize it afterwards. I know people accross the street from me, in MD anderson cancer center are making a lot of breakthroughs lately, but as you probably know MD anderson is not a tradable company, although I do believe they sell the drug candidates and commercialization rights to proper pharma companies which then put them out in the market. I can provide advice on whether the science behind some hyped biotech is feasible, or if it has better alternatives, **but** chatgpt can probably tell you which drugs have been taken into clinical trials, what stage they are in, and which companies are capable of scaling them enough to get FDA approval and create significant streams of income, much better than I can.

Joe_Early_MD

How will i get through the day 😒 u/Joe_Early_MD is permanently banned from r/OUTFITS

Worried_Quarter469

I only vote Republican -Michael Beary, MD

Ok-Parfait-9856

The only thing GLP1 agonists and IL-15 agonists have in common is that they’re agonists…comparing this drug to GLP1 agonists is ridiculous. GLP1 and IL-15 have literally nothing to do with each other. IL-15 isnt some secret. Agonizing it does stimulate the immune system but many cancers grow specifically because they avoid the immune system. So T cells and NK cells won’t do shit. It’s likely a great add-on treatment, but only if the cancer hasn’t already mutated to the point of avoiding the immune system. That’s why CAR-T therapy is so effective, it’s essentially extracting the patients T cells, then training T cells in the lab to target and attack cancer cells by using crispr to add the gene coding for a marker in the cancer cells, then reintroducing the modified T cells to the body. I know and worked in the same lab as a doctor (PhD MD dual degree) who’s pioneered CAR-T therapy; now he’s an expert. Sadly CAR-T isn’t a profitable drug but rather an expensive procedure, so profits are low but it’s the literal cure to cancer, due to its highly personalized nature. Since every cancer is different, there’s no one size fits all approach, but I digress. If your T cells are blind to cancer cells, which happens a lot, activating them won’t do anything. This drug, like many others, is a gamble. I work in biotech and have developed cancer therapies fwiw, and know much more than the average redditor…who knows nothing about biology besides a high school class they slept through. I don’t consider myself an expert, but my definition of an expert in this case would be someone who has a phd in cancer biology or immunology at the least, plus relevant research experience. And no, being an expert in IT or CS or finance doesn’t make you an expert in cancer biology and immunology.

Atlas-Scrubbed

While I was in graduate school, we lived next to a MD who was doing his residency. His comment was, never invest in what an MD invests in. His rationale was that MDs. Have lots of money but very little time to think about their investments… and so they made lots of really bad investments.

Ok_Insurance_6746

You have no idea about his skill set, he could be a lawyer or MD for all we know. Not every industry has a completely fucked job market

miata_only

For it's size the MD-11 carries more cargo than anything else. It's smaller size allows it to operate out of a wider variety of airports. There's a reason it was still used for cargo it's not easy to replace. The accident aircraft also wasn't even made by Boeing. McDonald Douglas still existed when N259UP was made in 1991 but Reddit won't care about that either it's all $BA's fault

Bowdallen

MAXQ is canadian penny stock, gonna be the first satelite launch pad in Canada most likely, up 50% this month so idk if i'd wait for a dip or what though MD Space is also a Canadian space stock and they invested into MAXQ i hold both as a combo

TheHyperboley


hv876

House MD has been over for 13 years

Upstairs_Tip_8596

Thank you for being a responsible parent. You’ve done him a solid. My dad left me with debt. problems and more problems. But it’s okay, I was resilient. I got my MD, started saving from 18 and I luckily found a bf who paid all my bills and student loans. So i’m not complaining! Even a bad hand doesn’t mean you’ll have a bad life.

NumberOneStonecutter

My firm had an ex-politician like an Eric Cantor, he was very hands-on and made sure everyone knew he wasn't just a 'Vice-Chair', but also an MD. Funnily enough, they hired his political 'Chief of Staff' too as an MD and he washed out pretty quickly because he just wasn't skilled in finance. I remember one night staying late to help him with a pitch for an infrastructure deal - up his alley because it involved political influence...but he was lost on the finance side. I wasn't apart of that group at all but we were casual friends and I wanted to try to help him. I think he went right back into politics.